Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SentoClone Significantly Strengthens its Global Patent Portfolio

Published: Friday, June 07, 2013
Last Updated: Friday, June 07, 2013
Bookmark and Share
New patents granted in Japan, the USA and Europe.

SentoClone International AB has announced that it has been granted additional patents in Japan, the US and Europe further reinforcing the global protection of its proprietary SentoClone® technology, an active patient specific cellular immunotherapy against cancer based on the ex vivo cultivation and activation of CD4+ T-cells.

The technology has advanced to Phase II clinical trials following Phase I and pilot studies in patients with colorectal and bladder cancer.

SentoClone International´s chairman Pingsheng Hu said, "We are determined to develop our SentoClone® technology as rapidly as possible so that it can become an effective patient specific cancer therapy without significant side effects for the broad range of cancer patients worldwide. The recent patents we have been granted in Japan, the US and Europe means we have very solid IP in all major markets in the field of sentinel node derived T-cells in cancer therapy. We believe this much stronger patent protection will allow us to attract development partners so that we can make this novel approach to cancer therapy available to the many patients globally who could benefit."

The SentoClone® technology builds on a unique approach whereby CD4+ T- helper cells, highly specific for the patient’s individual tumor, are extracted from the tumor’s draining lymph node (the sentinel node) and cultivated ex vivo in a GMP production facility before being returned to the patient via one single infusion.

During cultivation, the T-cells are stimulated with growth factors and re-activated with antigen from the patient’s individual tumor.

Once returned to the patient the T-cells induce effector cells of the immune system to attack the tumor tissue highly specifically, leaving other tissue unaffected.

Evidence indicates that the technology also generates a powerful long-term immunologic memory where T-cells are patrolling the body in a process called immunosurveillance.

To-date more than 200 patients with a range of cancers have been treated using this unique approach with no significant side effects being reported.

The safety profile, combined with its synergistic mode of action, suggest that SentoClone® technology could be an ideal addition to current or upcoming cancer treatment regimens.

The recent patents granted to SentoClone covering its Sentinel node-derived CD4 T-cell cancer therapy are as follows:
• In Japan, patent 5244610, titled “Improved method for expansion of tumour-reactive T-lymphocytes for immunotherapy in cancer” covers the process of ex vivo cultivation and activation of CD4+ T-cells. It is the Company´s second patent granted in Japan during 2013.
• In Europe, patent EP 1966370B1, titled “Method for obtaining T-lymphocytes” covers the use in cancer immunotherapy of T-cells derived from metastasis-draining lymph nodes (“metinel nodes”). It is the Company´s third European patent and is presently being validated in the major European countries.
• In the USA, patent US 8211425B2, titled “Method for treating disseminated cancer” is the Company´s sixth patent granted in the US and covers the use of metinel node T-cells in cancer immunotherapy.

SentoClone International holds 24 international patents, including these new grants, within eight families.

The portfolio comprises six patents in the USA, three patents in Europe and two patents in Japan.

In addition, SentoClone International’s Chinese parent company Jiangsu Sinorda Biomedicine Co. holds patents for the Chinese market.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Genes That Increase Children's Risk Of Blood Infection Identified
A team led by Oxford University has identified genes that make certain children more susceptible to invasive bacterial infections by performing a large genome-wide association study in African children.
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!